Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD
Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD
The purpose of this study is to determine the safety and tolerability of RO7239361 in boys
 with Duchenne Muscular Dystrophy with any genetic mutation.
Inclusion Criteria:

 -  Diagnosed with DMD

 -  Able to walk without assistance

 -  Able to walk up 4 stairs in 8 seconds or less

 -  Weigh at least 15 kg

 -  Taking corticosteroids for DMD

 Exclusion Criteria:

 -  Ejection fraction < 55% on echocardiogram, based on central read

 -  Any behavior or mental issue that will affect the ability to complete the required
 study procedures

 -  Previously or currently taking medications like androgens or human growth hormone

 -  Use of a ventilator during the day

 -  Unable to have blood samples collected or receive an injection under the skin

 -  Treatment with exon skipping therapies 6 months prior to study start

 -  Treatment with ataluren or any investigational drug currently or within 5 half-lives
 prior to study start